Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arstasis Inc.
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
With an annual growth of almost 5%, the market for vascular access site repair products is attracting companies with innovative new products. Wider acceptance of new approaches to wound closure by interventionalists and the under-penetration in emerging Asian markets in particular are resulting in an uptake in the use of higher-tech devices and the emergence of local manufacturers.
Medical device company financing brought in $977 million, a decrease over Q1’s $1.1 billion. Device acquisition activity was up to $4.6 billion, yet only one deal surpassed the billion-dollar mark. With late-stage financing again leading, diagnostics funding together brought in $336 million, an 11% increase over Q1. For the first time since Q1 2011, the diagnostics M&A dollar total moved up instead of down, with $7 billion in acquisitions and five of the seven transactions topping $100 million.
A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.
- Medical Devices